Abstract
Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Current Alzheimer Research
Title:Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Volume: 15 Issue: 8
Author(s): Cassandra Morrison*, Sheida Rabipour, Frank Knoefel, Christine Sheppard and Vanessa Taler
Affiliation:
- School of Psychology, University of Ottawa, Ottawa, ON, Canada, Bruyère Research Institute, Ottawa, ON,Canada
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Abstract: Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Export Options
About this article
Cite this article as:
Morrison Cassandra*, Rabipour Sheida , Knoefel Frank , Sheppard Christine and Taler Vanessa , Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (8) . https://dx.doi.org/10.2174/1567205015666180123123209
DOI https://dx.doi.org/10.2174/1567205015666180123123209 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrous Cycle and HIV-1 Tat Protein Influence Cocaine-Conditioned Place Preference and Induced Locomotion of Female Mice
Current HIV Research Drug Treatment of Obesity: Established and Emerging Therapies
Mini-Reviews in Medicinal Chemistry Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography
Current Pharmaceutical Design Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Editorial Review 2015
Current Radiopharmaceuticals Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Synthesis and First Evaluation of [<sup>18</sup>F]Fluorocyano- and [<sup>18</sup>F]Fluoronitroquinoxalinedione as Putative AMPA Receptor Antagonists
Medicinal Chemistry Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews Design, Synthesis and Anticonvulsant Activity Evaluation of 7-Substituted –[1,2,4]-Triazolo[4,3-f]Pyrimidine Derivatives
Medicinal Chemistry Synthesis and Evaluation of N-substituted (Z)-5-(Benzo[d][1,3]dioxol-5- ylmethylene)-2-Thioxothiazolidin-4-one Derivatives and 5-Substituted- Thioxothiazolidindione Derivatives as Potent Anticonvulsant Agents
CNS & Neurological Disorders - Drug Targets Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Cell Biological Consequences of Mitochondrial NADH: Ubiquinone Oxidoreductase Deficiency
Current Neurovascular Research Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Prader-Willi Syndrome: Genetics, Phenotype, and Management
Current Psychiatry Reviews Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued)